28 February 2020
Visiongain has launched a new pharma report Global Bioprocess Optimisation & Digital Biomanufacturing Market Forecast.
The Global market for bioprocess optimisation and digital biomanufacturing is favoured by the increasing global population which by 2050 will be predominately 65 years and above. There is also a growing demand for biologics drugs and biosimilar drugs which has compelled manufacturers to introduce technologies that would help bring the drugs to the market at a far more rapid pace than before.
The lead analyst of the report commented "The Bioprocess Optimization and Digital Manufacturing market is expected to witness a robust growth during the years of forecast owing to rise in biosimilars, growing complexity of drug manufacturing and patent expiry of blockbuster drugs coupled with rising cost containment pressure on biopharmaceutical players which is also expected to improve the uptake of digitally advanced products for manufacturing. With respect to the technology market, the analytical and process control technologies are expected to witness the highest growth during the forecast period. The bioreactors market is expected to foresee the highest growth during the forecast period."
Leading companies featured in the report include ABB, 3M Co., Danaher Corporation, Agilent Technologies, Applikon Technology, Sartorius Stedium Biotech, Shimadzu Corp., Siemens Healthcare and many others.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 207 336 6100.
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.
21 July 2021
Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.
20 July 2021
Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.
14 July 2021
Digital innovation in clinical trials and renewed focus on home production will ensure a high growth market for supply chain optimisation.